Itolizumab

Names

[ Name ]:
Itolizumab

Biological Activity

[Description]:

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[Target]

CD6[1]

[In Vitro]

Itolizumab (100 μg/mL) inhibits T cell proliferation[4]. Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs[4]. Itolizumab (40 μg/mL) reduces CD26hiCD161+ CD8+ T cells during culture of PBMCs overnight[5]. Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions[6].

[In Vivo]

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)[7]. Animal Model: Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)[7] Dosage: 60 μg or 300μg Administration: Intraperitoneal injection (i.p.), prior to PBMC transplantation. Result: Decreased mortality compared to the vehicle (100% vs. 10%).

[References]

[1]. Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34.

[2]. Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031.

[3]. Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421.

[4]. Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435.

[5]. Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688.

[6]. Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088.

[7]. Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.